NCT04197297
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have at least one lesion with diameter greater than 1cm & without evidence of bleeding; Patient must be planning to have radiotherapy to brain metastases
Exclusions: Patients who have received prior whole brain radiotherapy (WBRT) or radiosurgery to the brain lesion to be treated in the study
https://ClinicalTrials.gov/show/NCT04197297